A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Siu, L; Even, C; Mesia, R; Daste, A; Krauss, J; Saba, NF; Nabell, L; Ready, NE; Brana Garcia, I; Kotecki, N; Zandberg, DP; Gilbert, J; Mehanna, H; Jarkowski, A; Melillo, G; Armstrong, JM; Fayette, J

Published Date

  • April 1, 2018

Published In

Volume / Issue

  • 100 / 5

Start / End Page

  • 1307 - 1307

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1879-355X

International Standard Serial Number (ISSN)

  • 0360-3016

Conference Name

  • Multidisciplinary Head and Neck Cancers Symposium

Conference Location

  • Scottsdale, AZ

Conference Start Date

  • February 15, 2018

Conference End Date

  • February 17, 2018